648422-58-6

Upstream product

• 626-43-7 3,5-Dichloroaniline 
• 630-19-3 pivalaldehyde 
• 302840-63-7 (1R)-[1-(3,5-dichloro-phenylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester 
• 648422-57-5 (2S,5R)-2-tert-butyl-3-(3,5-dichlorophenyl)-5-methyl-imidazolidin-4-one 
• 302840-64-8 (2R)-2-amino-N-(3,5-dichlorophenyl)-propionamide 
• 589-15-1 1-bromomethyl-4-bromobenzene 
• 321724-17-8 (2S,5R)-2-tert-butyl-3-(3,5-dichlorophenyl)-5-methyl-1-trifluoroacetyl-imidazolidin-4-one 

Downstream Products

• 213208-73-2 (5R)-5-(4-bromobenzyl)-3-(3,5-dichlorophenyl)-5-methyl-1H-imidazole-2,4(3H,5H)-dione 
• 835917-10-7 {[2-(4-bromo-phenyl)-1-(3,5-dichloro-phenylcarbamoyl)-1-methyl-ethylcarbamoyl]-methyl}-carbamic acid tert-butyl ester 
• 302840-67-1 (2R)-2-amino-3-(4-bromophenyl)-N-(3,5-dichlorophenyl)-2-methyl-propionamide 

Relevant academic research and scientific papers

Synthesis of 6,7-Dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides

Disclosed is an improved multi-step process for preparing a compound of Formula I: wherein R1 to R3 are as defined herein. The compounds of formula I inhibit the binding of human intercellular adhesion molecules to the Leukointegrins

Synthesis of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides

Disclosed is a multi-step process for preparing a compound of Formula I: wherein R1 to R3 are as defined herein. The compounds of formula I inhibit the binding of human intercellular adhesion molecules to the Leukointegrins. As a res

A practical synthesis of highly functionalized fused 1,6-dihydroimidazo-[1, 2-a]imidazole-2,5-diones, key intermediates for LFA-1 inhibitors

An alternative and chromatography-free approach for synthesis of a new class of LFA-1 inhibitors was developed. A key feature of this process involved a transformation of thioureas 14 to acyclic guanidine derivatives 9 followed by intramolecular cyclizati

Practical synthesis of a cell adhesion inhibitor by self-regeneration of stereocenters

An efficient enantiospecific synthesis of the cell adhesion inhibitor BIRT-377 by self-regeneration of stereocenters has been achieved in 38% overall yield in eight steps. The key transformations involve the stereoselective formation of the trans imidazol

Self-regeneration of stereocenters: A practical enantiospecific synthesis of LFA-1 antagonist BIRT-377

An efficient enantiospecific synthesis of the LFA-1 antagonist BIRT-377 has been achieved in 43percent overall yield in eight steps. The key transformations involve the stereospecific formation of the trans imidazolidinone 7, subsequent alkylation, and th